Rising tides: the surge and thirst for the GLP-1s
GLP-1 receptor agonist products — a snapshot
The ongoing journey to market dominance
The GLP-1 RA product space is buzzing with sales growth and development activity. Established drugs such as Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s SC tirzepatide (Mounjaro / Zepbound) are dominating the market, while ongoing research is focused on developing novel mechanisms combined with GLP-1 RAs, such as Amgen’s MariTide and Eli Lilly’s retatrutide, aimed at improving efficacy, reducing side effects, and easing administration.
GLP-1 RA products are not typically used as a first-line therapy and are usually reserved for severe disease stages. However, their impressive efficacy in reducing HbA1c levels, body weight, and cardiovascular risks is driving strong increases in drug sales and patient share. The demand for these therapies is high.
This report explores the rapidly increasing demand for GLP1 RA products while also addressing questions such as:
- What impact will the increased use of GLP-1 RA products have on other antidiabetic drugs?
- What impact will the GLP-1 RA products have on the obesity market?
- How are physicians managing their T2D patients during the shortage?
- How are the MCOs handling the off-label use of GLP-1 RA products?
Download the report to find out more.
